Jamie Wang

[NDT @NDTsocial]

RAAS blockade in the kidney life-cycle: treatment standard

🔓https://t.co/m2mhZTjAJL

[Daniel J Drucker @DanielJDrucker]

A reminder of the benefits of exercise for cardiovascular health. In adults with #obesity, regular physical activity over 52 wks, with or without GLP-1R agonists, but not liraglutide alone, promotes vascular health & ⬇️CMT over in adults with obesity. https://t.co/366vC4XeMv

[Scott Isaacs @scottisaacsmd]

Sex, not age, predicts #tirzepatide response. In a Mayo Clinic cohort (n=1,039), women on ≥12 months of tirzepatide lost more weight than men, while age was not an independent predictor.
https://t.co/zXkEK6Ohts

[Scott Isaacs @scottisaacsmd]

Microdosing tirzepatide with multi‑dose Mounjaro KwikPens means carefully counting clicks to match the intended dose, guided by detailed pen instructions, but we still need real‑world safety and efficacy data before this off‑label approach can be considered standard care.
https://t.co/grPPnxRwcq

[Eric Topol @EricTopol]

GLP-1 drugs for people with both obesity and autoimmune diseases. The drugs were linked to reduced mortality, stroke, pulmonary embolism, and emergency room visits. From a new propensity matched analysis of 13,204 GLP-1 drug users and 13,204 controls
https://t.co/2ik57mwRW0

[Scott Isaacs @scottisaacsmd]

New UK expert consensus on MASH: use 2-step non-invasive testing to identify at-risk patients, pair pharmacotherapy with lifestyle support, and monitor response with liver stiffness over time.
https://t.co/cCM7B8Uz7A

[Michael Weintraub, MD @MWeintraubMD]

When should you prescribe Oral Wegovy or Foundayo?

Practical advantages/differences of each, just presented at ECO

HT Martin Haluzík

[Nature Reviews Drug Discovery @NatRevDrugDisc]

The evolving landscape of obesity pharmacotherapy
https://t.co/g87Q1eGjgT
https://t.co/WBz2UaPWU2

This new Review covers the evolution of obesity therapy from GLP1s to multi-receptor agonists, oral formulations, weight-loss quality approaches and tissue-specific drug targeting

[Eric Topol @EricTopol]

Two new randomized studies just published @NatureMedicine for weaning from injectable GLP-1 drugs to maintain weight loss
—Pill, orforglipron https://t.co/r9Nx9J9vJg
—Bacterial supplement for gut microbiome https://t.co/km2V3NkIOX

[Michael Weintraub, MD @MWeintraubMD]

🚨 SURMOUNT-MAINTAIN published in Lancet today

💉 Individuals after 60 weeks of high dose tirzepatide randomized to maintaining high dose vs. reduce dose to 5mg vs. placebo and followed for a 52 week maintenance period.

📊 After the 52 week maintenance period:
⬇️ High dose tirzepatide: 21.9% weight loss
⬇️ 5mg tirzepatide: 16.6% weight loss
⬇️ Placebo: 9.9% weight loss

🔑 Long-term treatment is necessary to maintain bodyweight reduction and its associated cardiometabolic benefits. Lowering the dose leads to variable degrees of weight regain. Discontinuation more definitely leads to weight regain.

https://t.co/71P0cNtXVN

[Cristobal Morales @CristobMorales]

https://t.co/pJ4Z0N4mbr Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO): 2026 update #ECO2026 @SociedadSeedo

[Cristina Tejera @cristinatejerap]

Orforglipron oral mantiene el 75-79% del peso perdido con tirzepatida/semaglutida tras 1 año vs 38-49% con placebo (p<0,001). ATTAIN-MAINTAIN confirma que la secuencia inyectable→oral es factible y clínicamente relevante. #eco2026

@NatureMedicine

🔗 https://t.co/b1dNNYpqCH

[Scott Isaacs @scottisaacsmd]

New JAMA Intern Med meta-analysis of 64 GLP-1 RA RCTs: women lost more weight than men on GLP-1s, but effects were otherwise consistent across age, race/ethnicity, BMI, and HbA1c. Precision meds are great, but here the “average” effect really does generalize.
https://t.co/mOps4WuQQc

[Scott Isaacs @scottisaacsmd]

GLP-1/GIP/PPAR “quintuple” agonism: a GLP-1–GIP–lanifibranor conjugate beat both #semaglutide and GLP-1/GIP alone on weight, glycemia, insulin sensitivity, liver inflammation and CV parameters, using a much lower #lanifibranor dose than stand‑alone PPAR agonism.
https://t.co/tUfqarrT5m

[Ahmed Bennis MD 🫀 @drbennisahmed]

🚨 CKM Syndrome — ARIC Study (n=5,705)
Only 0.4% of adults have NO cardio-kidney-metabolic risk factors.
Meanwhile → 56% are already at Stage 3 (subclinical CVD + high-risk CKD) and 32.6% at Stage 4 (MI, HF, Stroke, AF, PAD).
Heart. Kidney. Metabolism. One disease. One strategy.
The era of treating them in silos is over. 🫀🩺
#CKMSyndrome #Cardiology #Nephrology #T2D #CKD #Prevention

[Prof Kamlesh Khunti @kamleshkhunti]

Review: Metabolic liver disease: A summary of major guidelines and identifying opportunities to improve future guidelines

https://t.co/iOkWK2QdDO

[Scott Isaacs @scottisaacsmd]

The genetics of obesity: This new @NatMetabolism review shows obesity is highly heritable, with more than 85 monogenic forms and over 1,000 GWAS loci, and is rapidly opening the door to true precision medicine (MC4R agonists, PRSs, genotype-guided therapies) for our patients living with obesity.
https://t.co/zfSgCkwx5x

[Henry Han @HanCardiomd]

GLP-1R–GIPR–PPARα/γ/δ quintuple agonism corrects obesity and diabetes in mice

https://t.co/qZC5CKm14N

@Nature #CardioMetabolic #GLP1RA #GIP

[Scott Isaacs @scottisaacsmd]

HFpEF is a multiorgan syndrome. Obesity drives pathophysiology across 6 domains: metabolic dysfunction, mitochondrial impairment, vascular stiffness, cardiac remodeling, skeletal muscle abnormalities & chronic inflammation.
https://t.co/rynHn07Dps

[Daniel J Drucker @DanielJDrucker]

The leading GLP-1 medicine, tirzepatide, activates both the GIP and GLP-1 receptors, producing unsurpassed glucose control and weight loss. Yet human genetics and data from Maritide have spurred enthusiasm for molecules blocking the GIPR https://t.co/yeSQN2aAyZ